## C Noel Bairey-Merz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7149361/publications.pdf

Version: 2024-02-01

394 papers 40,250 citations

80 h-index 193 g-index

406 all docs

406 docs citations

406 times ranked 29600 citing authors

#	Article	IF	Citations
1	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004, 110, 227-239.	1.6	5,602
2	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014, 129, S1-45.	1.6	4,842
3	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology, 2014, 63, 2889-2934.	2.8	3,414
4	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology, 2004, 44, 720-732.	2.8	1,207
5	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S21-S29.	2.8	727
6	Cardiovascular Disease in Women. Circulation Research, 2016, 118, 1273-1293.	4.5	699
7	Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia. Journal of the American College of Cardiology, 2010, 55, 2825-2832.	2.8	660
8	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 2002, 106, 1024-1028.	1.6	657
9	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S4-S20.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the	2.8	620
10	American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the		

#	Article	IF	CITATIONS
19	Abnormal Myocardial Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy in Women with Chest Pain but Normal Coronary Angiograms. New England Journal of Medicine, 2000, 342, 829-835.	27.0	382
20	Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women. Circulation, 2004, 109, 726-732.	1.6	379
21	The Prognostic Value of a Nomogram for Exercise Capacity in Women. New England Journal of Medicine, 2005, 353, 468-475.	27.0	365
22	Abnormal Coronary Vasomotion as a Prognostic Indicator of Cardiovascular Events in Women. Circulation, 2004, 109, 722-725.	1.6	346
23	International standardization of diagnostic criteria for vasospastic angina. European Heart Journal, 2017, 38, ehv351.	2.2	325
24	The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease. Circulation, 2006, 114, 894-904.	1.6	299
25	Oxygenated Carotenoid Lutein and Progression of Early Atherosclerosis. Circulation, 2001, 103, 2922-2927.	1.6	297
26	Emergence of Nonobstructive CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2015, 66, 1918-1933.	2.8	257
27	Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiology, 2020, 5, 255.	6.1	249
28	Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. European Heart Journal, 2005, 27, 1408-1415.	2.2	238
29	Meditation and Cardiovascular Risk Reduction. Journal of the American Heart Association, 2017, 6, .	3.7	237
30	Depression, Inflammation, and Incident Cardiovascular Disease in Women With Suspected Coronary Ischemia. Journal of the American College of Cardiology, 2007, 50, 2044-2050.	2.8	234
31	Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women. Circulation, 2004, 109, 714-721.	1.6	231
32	Contraceptive Hormone Use and Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 221-231.	2.8	224
33	Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. Journal of the American College of Cardiology, 2003, 41, 413-419.	2.8	221
34	Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!. Journal of the American College of Cardiology, 2012, 60, 951-956.	2.8	216
35	The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia. American Heart Journal, 2009, 157, 548-555.	2.7	192
36	In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2011, 162, 678-684.	2.7	185

#	Article	IF	Citations
37	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke, 2002, 33, 2337-2341.	2.0	184
38	Effects of a Randomized Controlled Trial of Transcendental Meditation on Components of the Metabolic Syndrome in Subjects With Coronary Heart Disease. Archives of Internal Medicine, 2006, 166, 1218.	3.8	184
39	Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	184
40	Ranolazine Improves Angina in Women With Evidence of Myocardial Ischemia But No Obstructive Coronary Artery Disease. JACC: Cardiovascular Imaging, 2011, 4, 514-522.	5 <b>.</b> 3	180
41	Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 646-653.	2.9	177
42	Heart Rate Response to Exercise Stress Testing in Asymptomatic Women. Circulation, 2010, 122, 130-137.	1.6	176
43	Knowledge, Attitudes, and Beliefs Regarding Cardiovascular Disease inÂWomen. Journal of the American College of Cardiology, 2017, 70, 123-132.	2.8	172
44	An Intravascular Ultrasound Analysis in Women Experiencing Chest Pain in the Absence of Obstructive Coronary Artery Disease: A Substudy from the National Heart, Lung and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Interventional Cardiology, 2010, 23, 511-519.	1.2	162
45	Hypertension Across a Woman'sÂLifeÂCycle. Journal of the American College of Cardiology, 2018, 71, 1797-1813.	2.8	159
46	Some Thoughts on the Vasculopathy of Women With Ischemic Heart Disease. Journal of the American College of Cardiology, 2006, 47, S30-S35.	2.8	156
47	Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: Findings from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. American Heart Journal, 2013, 166, 134-141.	2.7	153
48	A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal, 2016, 37, 1504-1513.	2.2	152
49	Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes inÂWomen. Journal of the American College of Cardiology, 2019, 73, 684-693.	2.8	152
50	Depression, the Metabolic Syndrome and Cardiovascular Risk. Psychosomatic Medicine, 2008, 70, 40-48.	2.0	150
51	Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium. European Heart Journal, 2018, 39, 3727-3735.	2.2	141
52	Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease in Systemic Lupus Erythematosus. JACC: Cardiovascular Imaging, 2011, 4, 27-33.	<b>5.</b> 3	138
53	Psychosocial Stress and Cardiovascular Disease: Pathophysiological Links. Behavioral Medicine, 2002, 27, 141-147.	1.9	137
54	Coronary Microvascular Function and Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive Coronary Artery Disease: The iPOWER Study. Journal of the American Heart Association, 2016, 5, e003064.	3.7	131

#	Article	IF	CITATIONS
55	Pre-existing traits associated with Covid-19 illness severity. PLoS ONE, 2020, 15, e0236240.	2.5	129
56	The Value of Estimated Functional Capacity in Estimating Outcome. Journal of the American College of Cardiology, 2006, 47, S36-S43.	2.8	124
57	Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. American Heart Journal, 2013, 166, 38-44.	2.7	124
58	Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?. Journal of the American Heart Association, 2018, 7, e008868.	3.7	124
59	Career Preferences and Perceptions of Cardiology Among US Internal Medicine Trainees. JAMA Cardiology, 2018, 3, 682.	6.1	124
60	Myocardial Ischemia in Women: Lessons From the NHLBI WISE Study. Clinical Cardiology, 2012, 35, 141-148.	1.8	122
61	Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. Circulation, 2021, 143, 761-763.	1.6	118
62	Progression of Carotid Intima-Media Thickness and Plasma Antioxidants: The Los Angeles Atherosclerosis Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 313-319.	2.4	116
63	Depressive Symptom Dimensions and Cardiovascular Prognosis Among Women With Suspected Myocardial Ischemia. Archives of General Psychiatry, 2009, 66, 499.	12.3	116
64	Treatment of coronary microvascular dysfunction. Cardiovascular Research, 2020, 116, 856-870.	3.8	114
65	The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. European Heart Journal, 2017, 38, ehw461.	2.2	106
66	Assessment of Vascular Dysfunction inÂPatients Without Obstructive CoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1847-1864.	2.9	105
67	Comorbid Depression and Anxiety Symptoms as Predictors of Cardiovascular Events: Results From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Psychosomatic Medicine, 2009, 71, 958-964.	2.0	104
68	Provocative Testing for Coronary Reactivity andÂSpasm. Journal of the American College of Cardiology, 2014, 63, 103-109.	2.8	102
69	Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women. Circulation, 2002, 105, 2826-2829.	1.6	101
70	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Healthâ€"National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4985-4992.	3.6	101
71	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia. JAMA Cardiology, 2020, 5, 773.	6.1	101
72	Microvascular Coronary Dysfunction in Womenâ€"Pathophysiology, Diagnosis, and Management. Current Problems in Cardiology, 2011, 36, 291-318.	2.4	99

#	Article	IF	CITATIONS
73	The Who, What, Why, When, How and Where of Vasospastic Angina. Circulation Journal, 2016, 80, 289-298.	1.6	97
74	Prognostic Value of Global MR Myocardial Perfusion Imaging in Women With Suspected Myocardial Ischemia and No Obstructive Coronary Disease. JACC: Cardiovascular Imaging, 2010, 3, 1030-1036.	5.3	94
75	Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain. Journal of the American College of Cardiology, 2004, 43, 2009-2014.	2.8	93
76	Hypertension, Menopause, and Coronary Artery Disease Risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S50-S58.	2.8	88
77	Revascularization in Patients With Spontaneous Coronary Artery DissectionÂand ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 1290-1300.	2.8	87
78	Quality and Equitable Health Care Gaps forÂWomen. Journal of the American College of Cardiology, 2017, 70, 373-388.	2.8	86
79	Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clinical Cardiology, 2007, 30, 69-74.	1.8	85
80	Maternal Recall of Hypertensive Disorders in Pregnancy: A Systematic Review. Journal of Women's Health, 2013, 22, 37-47.	3.3	85
81	Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nature Reviews Cardiology, 2015, 12, 406-414.	13.7	85
82	Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. European Heart Journal, 2021, 42, 4592-4600.	2.2	84
83	Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	82
84	Depression and Cardiovascular Health Care Costs Among Women With Suspected Myocardial Ischemia. Journal of the American College of Cardiology, 2009, 53, 176-183.	2.8	80
85	The Impact of Myocardial Flow Reserve on the Detection of Coronary Artery Disease by Perfusion Imaging Methods: An NHLBI WISE Study. Journal of Cardiovascular Magnetic Resonance, 2003, 5, 475-485.	3.3	79
86	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. Journal of the American College of Cardiology, 2014, 64, 394-402.	2.8	79
87	Symptoms, myocardial ischaemia and quality of life in women: Results from the NHLBI-sponsored WISE Study. European Heart Journal, 2003, 24, 1506-1514.	2.2	77
88	Large brachial artery diameter is associated with angiographic coronary artery disease in women. American Heart Journal, 2002, 143, 802-807.	2.7	76
89	Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. Journal of the American College of Cardiology, 2002, 40, 1877-1881.	2.8	74
90	Depression Symptom Severity and Reported Treatment History in the Prediction of Cardiac Risk in Women With Suspected Myocardial Ischemia. Archives of General Psychiatry, 2006, 63, 874.	12.3	74

#	Article	IF	CITATIONS
91	Coronary Microvascular Dysfunction ― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy ―. Circulation Journal, 2017, 81, 3-11.	1.6	73
92	Association of Adverse Pregnancy Outcomes With Hypertension 2 to 7ÂYears Postpartum. Journal of the American Heart Association, 2019, 8, e013092.	3.7	72
93	Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. Fertility and Sterility, 2006, 85, 1425-1431.	1.0	69
94	Social Networks and Incident Stroke Among Women With Suspected Myocardial Ischemia. Psychosomatic Medicine, 2008, 70, 282-287.	2.0	69
95	The Yentl syndrome is alive and well. European Heart Journal, 2011, 32, 1313-1315.	2.2	68
96	Sex and the kidneys: current understanding and research opportunities. Nature Reviews Nephrology, 2019, 15, 776-783.	9.6	68
97	Determination of Menopausal Status in Women: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2004, 13, 872-887.	3.3	67
98	Persistent Chest Pain and No Obstructive Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2009, 301, 1468.	7.4	67
99	Global inflammation predicts cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. American Heart Journal, 2005, 150, 900-906.	2.7	65
100	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	3.3	65
101	Diastolic dysfunction: Improved understanding using emerging imaging techniques. American Heart Journal, 2010, 160, 394-404.	2.7	62
102	Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H14-H19.	3.2	62
103	Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive) Tj ETQq1	l 0.784314 1.8	rgBT  Overlo
104	Sex Differences in Mortality Associated With Computed Tomographic Angiographic Measurements of Obstructive and Nonobstructive Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2010, 3, 473-481.	2.6	60
105	Increasing Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction in the United States. JACC: Cardiovascular Interventions, 2015, 8, 139-146.	2.9	59
106	Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary Study. Clinical Cardiology, 2011, 34, 483-487.	1.8	58
107	Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). Menopause, 2017, 24, 126-132.	2.0	58
108	Electrocardiographic Predictors of Cardiovascular Outcome in Women. Journal of the American College of Cardiology, 2005, 46, 51-56.	2.8	57

#	Article	IF	CITATIONS
109	Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBIâ€Sponsored WISE Study. Journal of the American Heart Association, 2014, 3, e000660.	3.7	57
110	Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Instituteâ€Sponsored Women's Ischemia Syndrome Evaluation. Journal of the American Heart Association, 2019, 8, e012406.	3.7	56
111	Anginal Symptoms, Coronary Artery Disease, and Adverse Outcomes in Black and White Women: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2013, 22, 724-732.	3.3	55
112	Diastolic Dysfunction in Women With Signs and Symptoms of Ischemia in the Absence of Obstructive Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2014, 7, 510-516.	2.6	55
113	Isoflavone supplementation and endothelial function in menopausal women. Clinical Endocrinology, 2002, 56, 693-701.	2.4	54
114	Cardiac Syndrome X. Cardiology Clinics, 2014, 32, 463-478.	2.2	54
115	Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol. American Heart Journal, 2017, 191, 30-36.	2.7	53
116	Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. American Heart Journal, 2021, 237, 90-103.	2.7	51
117	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 54, 1336-1363.	2.8	50
118	Women, Hypertension, and the Systolic Blood Pressure Intervention Trial. American Journal of Medicine, 2016, 129, 1030-1036.	1.5	50
119	Psychosocial Variables Are Associated With Atherosclerosis Risk Factors Among Women With Chest Pain: The WISE Study. Psychosomatic Medicine, 2001, 63, 282-288.	2.0	49
120	Migraines, Angiographic Coronary Artery Disease and Cardiovascular Outcomes in Women. American Journal of Medicine, 2006, 119, 670-675.	1.5	49
121	Pregnancy as a Window to Future Cardiovascular Health: Design and Implementation of the nuMoM2b Heart Health Study. American Journal of Epidemiology, 2016, 183, 519-530.	3.4	49
122	Task force 4. Efficacy of risk factor management. Journal of the American College of Cardiology, 1996, 27, 991-1006.	2.8	48
123	Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?. European Heart Journal, 2018, 39, 850-852.	2.2	48
124	Patterns of leisure-time physical activity across pregnancy and adverse pregnancy outcomes. International Journal of Behavioral Nutrition and Physical Activity, 2018, 15, 68.	4.6	48
125	Gender in cardiovascular medicine: chest pain and coronary artery disease. European Heart Journal, 2019, 40, 3819-3826.	2.2	47
126	Physical Activity and Functional Capacity Measurement in Women: A Report from the NHLBI-Sponsored WISE Study. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 769-777.	1.5	45

#	Article	IF	Citations
127	Work-Related Stress and Early Atherosclerosis. Epidemiology, 2001, 12, 180-185.	2.7	45
128	Noninvasive Imaging toÂEvaluate Women With Stable Ischemic Heart Disease. JACC: Cardiovascular Imaging, 2016, 9, 421-435.	5.3	45
129	Contraception and Reproductive Planning for Women With CardiovascularÂDisease. Journal of the American College of Cardiology, 2021, 77, 1823-1834.	2.8	45
130	Importance of Socioeconomic Status as a Predictor of Cardiovascular Outcome and Costs of Care in Women with Suspected Myocardial Ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Women's Health, 2008, 17, 1081-1092.	3.3	43
131	Coronary Atherosclerosis T1-Weighed Characterization With Integrated Anatomical Reference. JACC: Cardiovascular Imaging, 2017, 10, 637-648.	5.3	43
132	Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2017, 12, e0177684.	2.5	43
133	Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. Cardiovascular Diagnosis and Therapy, 2013, 3, 153-60.	1.7	43
134	APOE polymorphism and angiographic coronary artery disease severity in the Women's Ischemia Syndrome Evaluation (WISE) study. Atherosclerosis, 2003, 169, 159-167.	0.8	41
135	Impaired Coronary Vascular Reactivity and Functional Capacity in Women. Journal of the American College of Cardiology, 2006, 47, S44-S49.	2.8	41
136	Focused Cardiovascular Care for Women. Mayo Clinic Proceedings, 2016, 91, 226-240.	3.0	41
137	Association of Spontaneous Preterm Delivery and Future Maternal Cardiovascular Disease. Circulation, 2018, 137, 865-871.	1.6	41
138	Effects of Sex and Gender on Adaptation to Space: Cardiovascular Alterations. Journal of Women's Health, 2014, 23, 950-955.	3.3	40
139	A Microvascular-Myocardial Diastolic Dysfunctional State and Risk for Mental Stress Ischemia. JACC: Cardiovascular Imaging, 2014, 7, 362-365.	5.3	40
140	Treatment of Angina and Microvascular Coronary Dysfunction. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 355-364.	0.9	39
141	A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Iournal. 2010. 159. 987.e1-987.e7.	2.7	39
142	Prognostic Significance of Nonobstructive Left Main Coronary Artery Disease in Women Versus Men. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	38
143	Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the Women's Ischemia Syndrome Evaluation study. Journal of Lipid Research, 2011, 52, 801-807.	4.2	37
144	Evaluating utility and compliance in a patient-based eHealth study using continuous-time heart rate and activity trackers. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1386-1391.	4.4	37

#	Article	IF	CITATIONS
145	Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction ancillary study. International Journal of Cardiology, 2019, 276, 8-13.	1.7	37
146	Sex Differences in Cardiovascular Aging and Heart Failure. Current Heart Failure Reports, 2020, 17, 409-423.	3.3	36
147	Effects of Oral Magnesium Therapy on Exercise Tolerance, Exercise-Induced Chest Pain, and Quality of Life in Patients With Coronary Artery Disease. American Journal of Cardiology, 2003, 91, 517-521.	1.6	35
148	Sex differences in ischemic heart disease and heart failure biomarkers. Biology of Sex Differences, 2018, 9, 43.	4.1	35
149	Cardiovascular implications of gender-affirming hormone treatment in the transgender population. Maturitas, 2019, 129, 45-49.	2.4	35
150	Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. American Heart Journal, 2005, 150, 109-115.	2.7	34
151	Syndrome X and Microvascular Coronary Dysfunction. Circulation, 2011, 124, 1477-1480.	1.6	34
152	Renal Function and Coronary Microvascular Dysfunction in Women with Symptoms/Signs of Ischemia. PLoS ONE, 2015, 10, e0125374.	2.5	34
153	Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2014, 167, 826-832.	2.7	33
154	Migraine Headache and Long-Term Cardiovascular Outcomes: An Extended Follow-Up of the Women's Ischemia Syndrome Evaluation. American Journal of Medicine, 2017, 130, 738-743.	1.5	33
155	Hostility Scores Are Associated With Increased Risk of Cardiovascular Events in Women Undergoing Coronary Angiography: A Report from the NHLBI-Sponsored WISE Study. Psychosomatic Medicine, 2005, 67, 546-552.	2.0	32
156	Towards elimination of the dark-rim artifact in first-pass myocardial perfusion MRI: Removing Gibbs ringing effects using optimized radial imaging. Magnetic Resonance in Medicine, 2014, 72, 124-136.	3.0	31
157	A randomized controlled trial of acupuncture in stable ischemic heart disease patients. International Journal of Cardiology, 2014, 176, 367-374.	1.7	31
158	Coronary Microvascular Dysfunction Causing Cardiac Ischemia in Women. JAMA - Journal of the American Medical Association, 2019, 322, 2334.	7.4	31
159	Socioeconomic Status Variables Predict Cardiovascular Disease Risk Factors and Prospective Mortality Risk among Women with Chest Pain. Behavior Modification, 2003, 27, 54-67.	1.6	30
160	Total Estrogen Time and Obstructive Coronary Disease in Women: Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Women's Health, 2009, 18, 1315-1322.	3.3	30
161	Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: An ancillary study from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2015, 170, 1243-1254.	2.7	30
162	Smoking status and common carotid artery intima-medial thickness among middle-aged men and women based on ultrasound measurement: a cohort study. BMC Cardiovascular Disorders, 2006, 6, 42.	1.7	29

#	Article	IF	CITATIONS
163	Diabetes Mellitus, Hypothalamic Hypoestrogenemia, and Coronary Artery Disease in Premenopausal Women (from the National Heart, Lung, and Blood Institute Sponsored WISE Study). American Journal of Cardiology, 2008, 102, 150-154.	1.6	29
164	Lipid-Lowering Medication Use and Aggression Scores in Women: A Report from the NHLBI-Sponsored WISE Study. Journal of Women's Health, 2008, 17, 187-194.	3.3	29
165	Timing of hormone therapy, type of menopause, and coronary disease in women. Menopause, 2011, 18, 943-950.	2.0	29
166	The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform. Expert Review of Proteomics, 2017, 14, 973-986.	3.0	29
167	Coronary Arterial Function and Disease in Women With No Obstructive Coronary Arteries. Circulation Research, 2022, 130, 529-551.	4.5	29
168	Heart failure hospitalization in women with signs and symptoms of ischemia: A report from the women's ischemia syndrome evaluation study. International Journal of Cardiology, 2016, 223, 936-939.	1.7	28
169	Heart–brain interactions in cardiac and brain diseases: why sex matters. European Heart Journal, 2022, 43, 3971-3980.	2.2	28
170	Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: The NHLBI-sponsored Women's Ischemia Syndrome Evaluation. International Journal of Cardiology, 2013, 168, 2335-2340.	1.7	27
171	The Case for Sex- and Gender-Specific Medicine. JAMA Internal Medicine, 2014, 174, 1348.	5.1	27
172	Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. Cardiovascular Drugs and Therapy, 2015, 29, 391-401.	2.6	27
173	Sex, Myocardial Infarction, and the Failure of Risk Scores in Women. Journal of Women's Health, 2015, 24, 859-861.	3.3	27
174	The Autonomic Nervous System and Cardiovascular Health and Disease. JACC: Heart Failure, 2015, 3, 383-385.	4.1	27
175	Phytoestrogens and Lipoproteins in Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2209-2213.	3.6	26
176	Adverse pregnancy outcomes and cardiovascular risk factor management. Seminars in Perinatology, 2015, 39, 268-275.	2.5	26
177	The Relationship of Menopausal Status and Rapid Menopausal Transition with Carotid Intima-Media Thickness Progression in Women: A Report from the Los Angeles Atherosclerosis Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4432-4440.	3.6	25
178	Gender and microvascular angina. Journal of Thrombosis and Thrombolysis, 2011, 31, 37-46.	2.1	25
179	Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease. Journal of Hypertension, 2013, 31, 1447-1455.	0.5	25
180	Identifying the Critical Gaps in Research on Sex Differences in Metabolism Across the Life Span. Endocrinology, 2018, 159, 9-19.	2.8	25

#	Article	IF	CITATIONS
181	Risk Stratification for Exercise Training in Cardiac Patients: Do the Proposed Guidelines Work?. Journal of Cardiopulmonary Rehabilitation and Prevention, 1999, 19, 118-125.	0.5	25
182	Cardiac Syndrome X. Heart Failure Clinics, 2016, 12, 141-156.	2.1	24
183	Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the women's ischemia syndrome evaluation (WISE). American Journal of Medicine, 2002, 113, 723-727.	1.5	23
184	TIMI Frame Count and Adverse Events in Women with No Obstructive Coronary Disease: A Pilot Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2014, 9, e96630.	2.5	23
185	Depression, Dietary Habits, and Cardiovascular Events Among Women with Suspected Myocardial Ischemia. American Journal of Medicine, 2014, 127, 840-847.	1.5	23
186	Sex and Ethnic Differences in Outcomes of Acute Coronary Syndrome and Stable Angina Patients With Obstructive Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S26-35.	2.2	23
187	Myocardial Scar Is Prevalent and Associated With Subclinical Myocardial Dysfunction in Women With Suspected Ischemia But No Obstructive Coronary Artery Disease. Circulation, 2018, 137, 874-876.	1.6	23
188	Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Journal of Translational Medicine, 2008, 6, 11.	4.4	22
189	Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine. Clinical Cardiology, 2017, 40, 300-306.	1.8	22
190	Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). Journal of Interventional Cardiology, 2019, 2019, 1-8.	1.2	22
191	Sex and Race/Ethnicity Differences in Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 2812-2815.	2.8	22
192	Associations of perceived prenatal stress and adverse pregnancy outcomes with perceived stress years after delivery. Archives of Women's Mental Health, 2020, 23, 361-369.	2.6	22
193	Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence. American Journal of Medicine, 2022, 135, 1059-1068.	1.5	22
194	Multimarker Approach Predicts Adverse Cardiovascular Events in Women Evaluated for Suspected Ischemia: Results from the National Heart, Lung, and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation. Clinical Cardiology, 2009, 32, 244-250.	1.8	21
195	Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval. Annals of Noninvasive Electrocardiology, 2013, 18, 389-398.	1.1	21
196	Sex, Death, and the Diagnosis Gap. Circulation, 2014, 130, 740-742.	1.6	21
197	All-systolic non-ECG-gated myocardial perfusion MRI: Feasibility of multi-slice continuous first-pass imaging. Magnetic Resonance in Medicine, 2015, 74, 1661-1674.	3.0	21
198	Mental stress peripheral vascular reactivity is elevated in women with coronary vascular dysfunction: Results from the NHLBI-sponsored Cardiac Autonomic Nervous System (CANS) study. International Journal of Cardiology, 2018, 251, 8-13.	1.7	21

#	Article	IF	CITATIONS
199	Fiveâ€Year Followâ€Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Communityâ€Based Lupus Cohort. Arthritis Care and Research, 2020, 72, 882-887.	3.4	21
200	Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia: Findings from the National Heart, Lung and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2005, 149, 527-533.	2.7	20
201	Is Cardiovascular Disease in Women Inevitable?. Cardiology in Review, 2011, 19, 76-80.	1.4	20
202	Combining Psychosocial Data to Improve Prediction of Cardiovascular Disease Risk Factors and Events. Psychosomatic Medicine, 2012, 74, 263-270.	2.0	20
203	Improving the quality of care for women with cardiovascular disease. American Heart Journal, 2008, 156, 816-825.e1.	2.7	19
204	Sudden Cardiac Death in Women With Suspected Ischemic Heart Disease, Preserved Ejection Fraction, and No Obstructive Coronary Artery Disease: A Report From the Women's Ischemia Syndrome Evaluation Study. Journal of the American Heart Association, 2017, 6, .	3.7	19
205	Myocardial ischemia: From disease to syndrome. International Journal of Cardiology, 2020, 314, 32-35.	1.7	19
206	Gender, Cardiovascular Disease, and the Sexism of Obesity â^—. Journal of the American College of Cardiology, 2015, 66, 1958-1960.	2.8	18
207	Women and Ischemic Heart Disease: Recognition, Diagnosis and Management. Korean Circulation Journal, 2016, 46, 433.	1.9	18
208	Women Are Less Likely Than Men to Be Full Professors in Cardiology. Circulation, 2017, 135, 518-520.	1.6	18
209	Heart failure with preserved ejection fraction: Similarities and differences between women and men. International Journal of Cardiology, 2020, 304, 101-108.	1.7	18
210	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome) Tj ETQq0 0 0 rgBT	/Osv.ørlock	1 <b>0.8</b> f 50 297
211	Cardiac magnetic resonance imaging for myocardial perfusion and diastolic function-reference control values for women. Cardiovascular Diagnosis and Therapy, 2016, 6, 78-86.	1.7	18
212	Nonacute Coronary Syndrome Anginal Chest Pain. Medical Clinics of North America, 2010, 94, 201-216.	2.5	17
213	New cholesterol guidelines and primary prevention in women. Trends in Cardiovascular Medicine, 2015, 25, 84-94.	4.9	17
214	Microvascular Angina: Diagnosis and Management. European Cardiology Review, 2021, 16, e46.	2.2	16
215	Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010802.	3.9	16
216	Comparison of SWAN and WISE Menopausal Status Classification Algorithms. Journal of Women's Health, 2006, 15, 1184-1194.	3.3	15

#	Article	IF	Citations
217	Mild renal dysfunction and long-term adverse outcomes in women with chest pain: Results from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2015, 169, 412-418.	2.7	15
218	Genetic loci associated with nonobstructive coronary artery disease in Caucasian women. Physiological Genomics, 2016, 48, 12-20.	2.3	15
219	Strategies and Methods for Clinical Scientists to Study Sex-Specific Cardiovascular Health and Disease in Women. Journal of the American College of Cardiology, 2016, 67, 2186-2188.	2.8	15
220	Sex and gender medicine in physician clinical training: results of a large, single-center survey. Biology of Sex Differences, 2016, 7, 37.	4.1	15
221	Psychosocial predictors of long-term mortality among women with suspected myocardial ischemia: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Journal of Behavioral Medicine, 2016, 39, 687-693.	2.1	15
222	Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). American Heart Journal, 2020, 220, 224-236.	2.7	15
223	Coronary microvascular dysfunction: Considerations for diagnosis and treatment. Cleveland Clinic Journal of Medicine, 2021, 88, 561-571.	1.3	15
224	Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Cardiovascular Diagnosis and Therapy, 2013, 3, 64-72.	1.7	15
225	Doing More Good than Harm: Need for a Cease Fire. American Journal of Medicine, 2009, 122, 315-316.	1.5	14
226	Sex-Specific Factors in Microvascular Angina. Canadian Journal of Cardiology, 2014, 30, 747-755.	1.7	14
227	Diastolic dysfunction measured by cardiac magnetic resonance imaging in women with signs and symptoms of ischemia but no obstructive coronary artery disease. International Journal of Cardiology, 2016, 220, 775-780.	1.7	14
228	Diversity is richness: why data reporting according to sex, age, and ethnicity matters. European Heart Journal, 2020, 41, 3117-3121.	2.2	14
229	Gender-Related Differences in Chest Pain Syndromes in the Frontiers in CV Medicine Special Issue: Sex & Lamp; Gender in CV Medicine. Frontiers in Cardiovascular Medicine, 2021, 8, 744788.	2.4	14
230	Association of N-Terminal Pro–Brain Natriuretic Peptide Concentration in Early Pregnancy With Development of Hypertensive Disorders of Pregnancy and Future Hypertension. JAMA Cardiology, 2022, 7, 268.	6.1	14
231	Plasma Apolipoprotein B Levels Predict Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease. Cardiology, 1999, 92, 151-155.	1.4	13
232	Stable angina in women: lessons from the National Heart, Lung and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Journal of Cardiovascular Medicine, 2011, 12, 85-87.	1.5	13
233	Contraception in Patients With Heart Failure. Circulation, 2012, 126, 1396-1400.	1.6	13
234	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause, 2021, 28, 610-618.	2.0	13

#	Article	IF	CITATIONS
235	Acetylcholine versus cold pressor testing for evaluation of coronary endothelial function. PLoS ONE, 2017, 12, e0172538.	2.5	13
236	Cardiac risk factors and myocardial perfusion reserve in women with microvascular coronary dysfunction. Cardiovascular Diagnosis and Therapy, 2013, 3, 146-52.	1.7	13
237	Ischemia and no obstructive coronary arteries in patients with stable ischemic heart disease. International Journal of Cardiology, 2022, 348, 1-8.	1.7	13
238	Small and large vessel disease in persons with unrecognized compared to recognized myocardial infarction: The TromsÃ, Study 2007–2008. International Journal of Cardiology, 2018, 253, 14-19.	1.7	12
239	Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines. European Heart Journal, 2018, 39, 3451-3453.	2.2	12
240	A protocol integrating remote patient monitoring patient reported outcomes and cardiovascular biomarkers. Npj Digital Medicine, 2019, 2, 84.	10.9	12
241	Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial. Journal of Women's Health, 2019, 28, 573-582.	3.3	12
242	Resting coronary velocity and myocardial performance in women with impaired coronary flow reserve: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. International Journal of Cardiology, 2020, 309, 19-22.	1.7	12
243	Quality Control and Outlier Detection of Targeted Mass Spectrometry Data from Multiplex Protein Panels. Journal of Proteome Research, 2020, 19, 2278-2293.	3.7	12
244	Left ventricular circumferential strain and coronary microvascular dysfunction: A report from the Women's Ischemia Syndrome Evaluation Coronary Vascular Dysfunction (WISE-CVD) Project. International Journal of Cardiology, 2021, 327, 25-30.	1.7	12
245	Early Pregnancy Atherogenic Profile in a First Pregnancy and Hypertension Risk 2 to 7ÂYears After Delivery. Journal of the American Heart Association, 2021, 10, e017216.	3.7	12
246	Associations of Insulin Resistance With Systolic and Diastolic Blood Pressure: A Study From the HCHS/SOL. Hypertension, 2021, 78, 716-725.	2.7	12
247	Sex―and Ageâ€Based Temporal Trends in Takotsubo Syndrome Incidence in the United States. Journal of the American Heart Association, 2021, 10, e019583.	3.7	12
248	Calcium Supplements and Cardiovascular Disease. American Journal of Lifestyle Medicine, 2015, 9, 298-307.	1.9	11
249	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction Study (WISE-CVD). Atherosclerosis, 2016, 253, 111-117.	0.8	11
250	Guidelines and Consensus: Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute. Pulmonary Circulation, 2016, 6, 143-143.	1.7	11
251	Intracoronary Bolus Injection Versus Intravenous Infusion of Adenosine for Assessment of Coronary Flow Velocity Reserve in Women With Signs and Symptoms of Myocardial Ischemia and No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 2125-2127.	2.9	11
252	Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study. International Journal of Cardiology, 2018, 270, 48-53.	1.7	11

#	Article	IF	CITATIONS
253	Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study. European Heart Journal Cardiovascular Imaging, 2019, 20, 875-882.	1.2	11
254	Ambulatory and silent myocardial ischemia in women with coronary microvascular dysfunction: Results from the Cardiac Autonomic Nervous System study (CANS). International Journal of Cardiology, 2020, 316, 1-6.	1.7	11
255	Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2021, 16, e0257184.	2.5	11
256	Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Research Protocols, 2017, 6, e255.	1.0	11
257	Microvascular Angina: An Underappreciated Cause of SLE Chest Pain. Journal of Rheumatology, 2013, 40, 746-747.	2.0	10
258	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
259	Coronary Vascular Function and Cardiomyocyte Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 3015-3021.	2.4	10
260	Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease: A Report from the WISE (Women's Ischemia Syndrome Evaluation) Study. Journal of the American Heart Association, 2020, 9, e013168.	3.7	10
261	Impact of STEMI Diagnosis and Catheterization Laboratory Activation Systems on Sex- and Age-Based Differences in Treatment Delay. CJC Open, 2021, 3, 723-732.	1.5	10
262	Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease. International Journal of Cardiology, 2021, 333, 35-39.	1.7	10
263	Mental Versus Physical Stress, QT Prolongation, and the Autonomic Nervous System. Circulation, 2000, 101, E213-4.	1.6	9
264	Cardiac syndrome X: Relation to microvascular angina and other conditions. Current Cardiovascular Risk Reports, 2007, 1, 167-175.	2.0	9
265	Task Force 10: Training in Preventive Cardiovascular Medicine. Journal of the American College of Cardiology, 2008, 51, 393-398.	2.8	9
266	Brachial Artery Constriction during Brachial Artery Reactivity Testing Predicts Major Adverse Clinical Outcomes in Women with Suspected Myocardial Ischemia: Results from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. PLoS ONE, 2013, 8, e74585.	2.5	9
267	Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). International Journal of Cardiology, 2014, 172, e114-e115.	1.7	9
268	Left atrial stiffness in women with ischemia and no obstructive coronary artery disease: Novel insight from left atrial feature tracking. Clinical Cardiology, 2020, 43, 986-992.	1.8	9
269	Sleep-disordered Breathing in Pregnancy and after Delivery: Associations with Cardiometabolic Health. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1202-1213.	5.6	9
270	Pulse Pressure and Adverse Outcomes in Women: A Report From the Women's Ischemia Syndrome Evaluation (WISE). American Journal of Hypertension, 2008, 21, 1224-1230.	2.0	8

#	Article	IF	Citations
271	Publicly Available Data. Journal of the American College of Cardiology, 2015, 66, 1973-1975.	2.8	8
272	Analysis of the Bypass Angioplasty Revascularization Investigation Trial Using a Multistate Model of Clinical Outcomes. American Journal of Cardiology, 2015, 115, 1073-1079.	1.6	8
273	The Risk of Remaining Silent: Addressing the Current Threats to Women's Health. Women's Health Issues, 2017, 27, 621-624.	2.0	8
274	Biometric and Psychometric Remote Monitoring and Cardiovascular Risk Biomarkers in Ischemic Heart Disease. Journal of the American Heart Association, 2020, 9, e016023.	3.7	8
275	Cardiometabolic Risk-Related Blood Pressure Trajectories Differ by Sex. Hypertension, 2020, 75, e6-e9.	2.7	8
276	Diastolic dysfunction in women with ischemia and no obstructive coronary artery disease: Mechanistic insight from magnetic resonance imaging. International Journal of Cardiology, 2021, 331, 1-7.	1.7	8
277	A Scientific Imperative as Seen Through a Sharpened Lens: Sex, Gender, and the Cardiovascular Condition. Circulation Research, 2022, 130, 433-435.	4.5	8
278	Intracellular Magnesium Predicts Functional Capacity in Patients with Coronary Artery Disease. Cardiology, 1998, 90, 168-172.	1.4	7
279	Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question. Maturitas, 2010, 65, 297-298.	2.4	7
280	Quantification of myocardial blood flow using non–ECGâ€ŧriggered MR imaging. Magnetic Resonance in Medicine, 2015, 74, 765-771.	3.0	7
281	Quantification of myocardial blood flow using non-electrocardiogram-triggered MRI with three-slice coverage. Magnetic Resonance in Medicine, 2016, 75, 2112-2120.	3.0	7
282	Pregnancy outcomes, reproductive history and cardiovascular disease risk in women: What do we know and what is needed?. European Journal of Preventive Cardiology, 2016, 23, 1860-1862.	1.8	7
283	Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve. Clinical Cardiology, 2017, 40, 886-891.	1.8	7
284	First-pass myocardial perfusion MRI with reduced subendocardial dark-rim artifact using optimized Cartesian sampling. Journal of Magnetic Resonance Imaging, 2017, 45, 542-555.	3.4	7
285	Coronary Microvascular Dysfunction in Patients With Systemic Lupus Erythematosus and Chest Pain. Frontiers in Cardiovascular Medicine, 2022, 9, 867155.	2.4	7
286	Phytoestrogens and Coronary Microvascular Function in Women with Suspected Myocardial Ischemia: A Report from the Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2007, 16, 481-488.	3.3	6
287	Subendocardial Ischemia and Myocarditis in Systemic Lupus Erythematosus Detected by Cardiac Magnetic Resonance Imaging. Journal of Rheumatology, 2012, 39, 448-450.	2.0	6
288	Improved quantification of myocardial blood flow using highly constrained back projection reconstruction. Magnetic Resonance in Medicine, 2014, 72, 749-755.	3.0	6

#	Article	IF	CITATIONS
289	Do women with statin-related myalgias have low vitamin D levels?. BMC Research Notes, 2015, 8, 449.	1.4	6
290	Advances in Lipid Therapy: The Role of Lipid Treatment in Women in Primary Prevention. Progress in Cardiovascular Diseases, 2016, 59, 178-189.	3.1	6
291	Women in Cardiovascular Clinical Trials—What Are the Barriers to Address to Improve Enrollment?. Canadian Journal of Cardiology, 2019, 35, 552-554.	1.7	6
292	The role of coronary reactivity testing in women with no obstructive coronary artery disease. Current Opinion in Cardiology, 2019, 34, 656-662.	1.8	6
293	Left ventricular mass and myocardial scarring in women with hypertensive disorders of pregnancy. Open Heart, 2020, 7, e001273.	2.3	6
294	Even "WISE-R?â€â€"an Update on the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation. Current Atherosclerosis Reports, 2020, 22, 35.	4.8	6
295	International prospective cohort study of microvascular angina – Rationale and design. IJC Heart and Vasculature, 2020, 31, 100630.	1.1	6
296	Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women?. European Journal of Preventive Cardiology, 2022, 29, 1608-1614.	1.8	6
297	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials. Contemporary Clinical Trials, 2022, 117, 106762.	1.8	6
298	Are we â€~WISE'r? Findings from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation Study. Women's Health, 2006, 2, 57-64.	1.5	5
299	Assessing Mature Technology. Journal of the American College of Cardiology, 2007, 49, 238-239.	2.8	5
300	Guidelines for Managing High Blood Pressure. JAMA - Journal of the American Medical Association, 2014, 312, 294.	7.4	5
301	Sex-specific precision medicine: targeting CRT-D and other cardiovascular interventions to those most likely to benefit. European Heart Journal, 2017, 38, 1495-1497.	2.2	5
302	Weight cycling and cardiovascular outcome in women with suspected ischemia: A report from the NHLBI-sponsored WISE Study. PLoS ONE, 2018, 13, e0207223.	2.5	5
303	Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2018, 206, 123-126.	2.7	5
304	Falseâ€positive stress testing: Does endothelial vascular dysfunction contribute to STâ€segment depression in women? A pilot study. Clinical Cardiology, 2018, 41, 1044-1048.	1.8	5
305	Adverse cardiovascular outcomes in women: blame the amygdala?. European Heart Journal Cardiovascular Imaging, 2019, 20, 633-635.	1.2	5
306	Not typical angina and mortality in women with obstructive coronary artery disease: Results from the Women's Ischemic Syndrome Evaluation study (WISE). IJC Heart and Vasculature, 2020, 27, 100502.	1.1	5

#	Article	IF	CITATIONS
307	Challenging Statin Pleiotropy: Preeclampsia. Circulation, 2021, 144, 680-683.	1.6	5
308	Cardiac Sympathetic Activity by 123I-Meta-Iodobenzylguanidine Imaging in Women With Coronary Microvascular Dysfunction. JACC: Cardiovascular Imaging, 2021, 14, 1873-1875.	5.3	5
309	Sexâ€Specific Temporal Trends in Hypertensive Crisis Hospitalizations in the United States. Journal of the American Heart Association, 2022, , e021244.	3.7	5
310	The Joint Impact of Smoking and Exercise Capacity on Clinical Outcomes among Women with Suspected Myocardial Ischemia: The WISE Study. Journal of Women's Health, 2009, 18, 443-450.	3.3	4
311	Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Cardiovascular Diagnosis and Therapy, 2018, 8, 405-413.	1.7	4
312	Vascular Function and Serum Lipids in Women with Spontaneous Preterm Delivery and Term Controls. Journal of Women's Health, 2019, 28, 1522-1528.	3.3	4
313	Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1â€Year Followâ€Up: Results From WISEâ€CVD. Journal of the American Heart Association, 2020, 9, e016305.	3.7	4
314	The Clinical Spectrum of Myocardial Infarction and Ischemia With Nonobstructive Coronary Arteries in Women. JACC: Cardiovascular Imaging, 2021, 14, 1053-1062.	5.3	4
315	Phytoestrogen blood levels and adverse outcomes in women with suspected ischemic heart disease. European Journal of Clinical Nutrition, 2021, 75, 829-835.	2.9	4
316	Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease. Journal of Women's Health, 2021, 30, 377-384.	3.3	4
317	Detection of subclinical atherosclerosis from PET-CT in patients with breast cancer. Journal of Cardiovascular Computed Tomography, 2022, 16, 189-190.	1.3	4
318	Changing Incidence and Mechanism of Pregnancyâ€Associated Myocardial Infarction in the State of California. Journal of the American Heart Association, 2021, 10, e021056.	3.7	4
319	Improved diagnosis and prognosis using Decisions Informed by Combining Entities (DICE): results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). Cardiovascular Diagnosis and Therapy, 2013, 3, 216-27.	1.7	4
320	Somatic versus cognitive depressive symptoms as predictors of coronary artery disease among women with suspected ischemia: The women's ischemia syndrome evaluation. Heart and Mind (Mumbai, India), 2021, 5, 112.	0.6	4
321	Cardiovascular Disease and Endometrial Cancer. Gynecologic Oncology, 2012, 126, 171-173.	1.4	3
322	Recognizing Sex SimilaritiesÂin Cardiovascular Disease Research. Journal of the American College of Cardiology, 2015, 65, 2152-2153.	2.8	3
323	Ischemic Predictors of Outcomes in Women With Signs and Symptoms of Ischemia and Nonobstructive Coronary Artery Disease. JAMA Cardiology, 2016, 1, 491.	6.1	3
324	Menopausal hormone therapy and national time trends in mortality: cautions regarding causal inference. Menopause, 2017, 24, 874-876.	2.0	3

#	Article	IF	CITATIONS
325	Aortic flow conditions predict ejection efficiency in the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Cardiovascular Diagnosis and Therapy, 2017, 7, 288-295.	1.7	3
326	Maladaptive left ventricular remodeling in women: An analysis from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction study. International Journal of Cardiology, 2018, 268, 230-235.	1.7	3
327	Sex Differences in the Cardiac Effects of Early-Onset Hypertension. Hypertension, 2019, 74, e52-e53.	2.7	3
328	Progression of coronary microvascular dysfunction to heart failure with preserved ejection fraction: a case report. Journal of Medical Case Reports, 2019, 13, 134.	0.8	3
329	Biology and bias: do we have the will to improve cardiovascular disease outcomes for women?. Heart, 2019, 105, 503-505.	2.9	3
330	Sex differences and the left ventricle: morphology matters. European Heart Journal Cardiovascular Imaging, 2020, 21, 991-993.	1.2	3
331	The Effects of Hormone Therapy on Inflammatory, Hemostatic, and Fibrinolytic Markers in Postmenopausal Women., 2007,, 471-480.		3
332	N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2020, 15, e0243213.	2.5	3
333	The differing prognostic utility of exercise radionuclide ventriculography in coronary artery disease patients with and without prior myocardial infarction. International Journal of Cardiovascular Imaging, 1997, 13, 403-413.	0.6	2
334	Time to Reevaluate Risk Stratification Guidelines for Medically Supervised Exercise Training in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2000, 283, 1476.	7.4	2
335	President's page: The promise of prevention: So, why aren't all cardiologists "preventive�. Journal of the American College of Cardiology, 2004, 44, 2082-2084.	2.8	2
336	Hormone Therapy in Women After Heart Transplantation. Transplantation Proceedings, 2013, 45, 3386-3388.	0.6	2
337	A Preliminary Investigation on the Acceptance and Feasibility of Acupuncture in the Intensive Care Unit. ICU Director, 2013, 4, 82-87.	0.2	2
338	Getting Guidelines Correct. Journal of the American College of Cardiology, 2015, 65, 2051-2052.	2.8	2
339	Prior myocardial infarction is associated with coronary endothelial dysfunction in women with signs and symptoms of ischemia and no obstructive coronary artery disease. International Journal of Cardiology, 2016, 207, 137-139.	1.7	2
340	Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease. Journal of Medical Case Reports, 2017, 11, 144.	0.8	2
341	Reassurance for many healthy women considering HRT. BMJ: British Medical Journal, 2017, 359, j4652.	2.3	2
342	Cold Pressor Stress Cardiac Magnetic Resonance Myocardial Flow Reserve Is Not Useful for Detection of Coronary Endothelial Dysfunction in Women with Signs and Symptoms of Ischemia and No Obstructive CAD. PLoS ONE, 2017, 12, e0169818.	2.5	2

#	Article	IF	Citations
343	Response to letter from Picich $\tilde{A}$ : The microvascular network connecting extracardiac arteries to the heart. International Journal of Cardiology, 2018, 259, 56.	1.7	2
344	Women's health. Current Opinion in Cardiology, 2018, 33, 506-513.	1.8	2
345	Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. Clinical Cardiology, 2021, 44, 1586-1593.	1.8	2
346	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. PLoS ONE, 2020, 15, e0240166.	2.5	2
347	Therapy for stable angina in women. P and T, 2012, 37, 400-4.	0.9	2
348	Stem Cell Therapy Targets: Repêchage!. Circulation Research, 2022, 130, 339-342.	4.5	2
349	Reply. Journal of the American College of Cardiology, 2013, 61, 388.	2.8	1
350	Cardiac Syndrome X: An Overview. , 2013, , 3-7.		1
351	Reply. Journal of the American College of Cardiology, 2016, 67, 2088.	2.8	1
352	Stroke in women: Where are we in 2015?. Trends in Cardiovascular Medicine, 2016, 26, 89-91.	4.9	1
353	My Approach to evaluating chest pain in the patient with no obstructive coronary artery disease. Trends in Cardiovascular Medicine, 2017, 27, 585-586.	4.9	1
354	Serotonin Transporter Gene Polymorphism in Women With Suspected Ischemia., 2018, 2, 8-15.	0.8	1
355	Recent Legislation, Public Policy Changes, and Women's Cardiovascular Health. Circulation, 2018, 138, 1082-1084.	1.6	1
356	Case report: assessment and management of myocardial infarction and non-obstructive coronary arteries (MINOCA): the role of microvascular coronary vasospasm. Cardiovascular Diagnosis and Therapy, 2019, 9, 400-405.	1.7	1
357	Cardiovascular and pregnancy outcomes in women with coronary microvascular dysfunction: a case series. European Heart Journal - Case Reports, 2019, 3, .	0.6	1
358	Coronary Microvascular Dysfunction. , 2021, , 141-158.		1
359	Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease. American Heart Journal Plus, 2022, 13, 100115.	0.6	1
360	Sex-based differences in remote monitoring of biometric, psychometric and biomarker indices in stable ischemic heart disease. Biology of Sex Differences, 2022, 13, 15.	4.1	1

#	Article	IF	Citations
361	Progression of Early Atherosclerosis and Intake of Vitamin C and Vitamin E from Supplements and Food. The <i>Los Angeles Atherosclerosis Study</i> ). Circulation, 2001, 103, 1365-1365.	1.6	1
362	Women and Heart Disease: Progress, Persistent Gaps, and Future Promise. Journal of Women's Health, 2006, 15, 12-13.	3.3	0
363	DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results From the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Obstetrical and Gynecological Survey, 2011, 66, 143-144.	0.4	0
364	Diagnosis and Treatment of Ischemic Heart Disease in Women. , 2013, , 975-989.		0
365	Letter by Bairey Merz et al Regarding Article, "A Shocking Development in a Young Male Athlete With Chest Pain― Circulation, 2016, 134, e20-1.	1.6	O
366	Endothelial Dysfunction and Coronary Microvascular Dysfunction in Women With Angina and Nonobstructive Coronaries., 2018,, 555-562.		0
367	Angina in Patients with Evidence of Myocardial Ischemia and No Obstructive Coronary Artery Disease. , 2018, , 374-390.		0
368	End-organ ischemia in the absence of proximal obstructive arterial disease: Déjà vu or jamais vu?. Atherosclerosis, 2019, 287, 162-164.	0.8	0
369	Risk factors for heart failure in women with ischemia and no obstructive coronary artery disease. American Heart Journal Plus, 2021, 8, 100035.	0.6	0
370	Younger Women Living with Chronic Disease: Comparative Challenges, Resiliencies, and Needs in Heart Disease and Breast Cancer. Journal of Women's Health, 2021, 30, 1288-1302.	3.3	0
371	Association of second trimester uterine artery Doppler parameters with maternal hypertension 2–7 years after delivery. International Journal of Cardiology Cardiovascular Risk and Prevention, 2021, 10, 200105.	1.1	0
372	Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project. , 2021, 5, .		0
373	Anemia and Long-term cardiovascular outcomes in women with suspected ischemia – The Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal Plus, 2021, 10, 100059.	0.6	O
374	Insights to advance our management of myocardial ischemia: From obstructive epicardial disease to functional coronary alterations. American Heart Journal Plus, 2021, 11, 100060.	0.6	0
375	Chest Pain with Normal Coronary Arteries: Future Directions. , 2013, , 343-345.		0
376	Cardiac Syndrome X Prognosis. , 2013, , 267-275.		0
377	Management of Pain., 2013,, 333-342.		0
378	Cardiovascular Disease in Women: An Update. , 2015, , 129-141.		0

#	Article	IF	Citations
379	Menopause and Cardiovascular Risk. , 2017, , 87-105.		O
380	Ischemic Heart Disease in Women. , 2017, , 33-53.		0
381	Female Manifestation of Acute Coronary Syndromes. , 2017, , 55-76.		O
382	Myocardial Infarction and Persistent Angina With No Obstructive Coronary Artery Disease. JACC: Case Reports, 2020, 2, 9-14.	0.6	0
383	Coronary microvascular dysfunction as a chronic inflammatory state: Is there a role for omega-3 fatty acid treatment?. American Heart Journal Plus, 2022, 13, 100098.	0.6	O
384	Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study. International Journal of Cardiovascular Imaging, 2022, , 1.	1.5	0
385	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
386	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
387	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
388	Pre-existing traits associated with Covid-19 illness severity. , 2020, 15, e0236240.		0
389	Title is missing!. , 2020, 15, e0240166.		0
390	Title is missing!. , 2020, 15, e0240166.		0
391	Title is missing!. , 2020, 15, e0240166.		0
392	Title is missing!. , 2020, 15, e0240166.		0
393	Internal Medicine Resident Education Improves Cardiac Rehabilitation Knowledge, Attitude, and Referral Rates: A Pilot Study. American Journal of Preventive Cardiology, 2022, , 100349.	3.0	0
394	Mortality Risk in Takotsubo Syndrome Versus Myocarditis. Journal of the American Heart Association, 2022, 11, .	3.7	0